News | December 04, 2013

Ziyad Hijazi Appointed Clinical Chief for Pediatrics at Sidra Medical and Research Center in Qatar

December 4, 2013 — Sidra Medical and Research Center, a specialty women's and children's hospital in Qatar, announced that Ziyad Hijazi, M.D., has been appointed clinical chief for pediatrics. In this role, the pioneering clinician will drive the strategic direction of the Department of Pediatrics and integrate research and education priorities into a program of excellent clinical service delivery. He will also hold the position of chair of pediatrics at Weill Cornell Medical College — Qatar, Sidra's partner for medical education.
"Sidra will be a beacon of excellence for pediatric care in Qatar and the Middle East so this is a key appointment for us," said Edward Ogata, chief medical officer, Sidra. "Dr. Hijazi's wide-ranging clinical and academic expertise in both pediatrics and cardiology, and his passion for research of the highest quality — evident from his exceptional record of publications — perfectly complement our vision for Sidra. I am particularly pleased that he will be here when Sidra hosts the Excellence in Pediatrics Conference 4-7 December, the first time this major conference has been held here in the Middle East."
Hijazi attended the Yale University School of Medicine, where he completed a Master of Public Health degree, a residency in Pediatrics and a fellowship in Pediatric Cardiology. He spent eight years on the faculty at Tufts University School of Medicine and another eight years at the University of Chicago. In 2007, he was appointed professor, Pediatrics and Internal Medicine, director, Rush Center for Congenital and Structural Heart Disease, and section chief, Pediatric Cardiology at Rush University Medical Center.
Hijazi specializes in treating congenital and structural heart disease in both children and adults. He is a pioneer in and considered one of the top experts in transcatheter repair of congenital and structural heart defects and a past president of the Society for Cardiovascular Angiography and Interventions (SCAI). 
"It's an honor to join Sidra and its prestigious leadership team,” said Hijazi. “I'm optimistic that my work with transcatheter septal defect closure in children, which will be the focus of my presentation at EiP, is helping find alternatives to the invasive open heart surgery which is especially traumatic for pediatric patients and I look forward to bringing these techniques to Sidra."
For more information:

Related Content

Gore Cardioform ASD Occluder Receives FDA Approval
Technology | Structural Heart Occluders | June 10, 2019
W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA)...
Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder
News | Structural Heart Occluders | February 13, 2019
Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's...
FDA Approves Abbott's Amplatzer Piccolo Occluder
News | Structural Heart Occluders | January 16, 2019
Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...
FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...